JP2017510641A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510641A5
JP2017510641A5 JP2017502932A JP2017502932A JP2017510641A5 JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5 JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017502932 A JP2017502932 A JP 2017502932A JP 2017510641 A5 JP2017510641 A5 JP 2017510641A5
Authority
JP
Japan
Prior art keywords
cancer
nitrogen
independently selected
oxygen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510641A (ja
JP6757312B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022841 external-priority patent/WO2015148854A1/en
Publication of JP2017510641A publication Critical patent/JP2017510641A/ja
Publication of JP2017510641A5 publication Critical patent/JP2017510641A5/ja
Application granted granted Critical
Publication of JP6757312B2 publication Critical patent/JP6757312B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502932A 2014-03-27 2015-03-26 置換インドールmcl−1阻害剤 Expired - Fee Related JP6757312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971023P 2014-03-27 2014-03-27
US61/971,023 2014-03-27
PCT/US2015/022841 WO2015148854A1 (en) 2014-03-27 2015-03-26 Substituted indole mcl-1 inhibitors

Publications (3)

Publication Number Publication Date
JP2017510641A JP2017510641A (ja) 2017-04-13
JP2017510641A5 true JP2017510641A5 (enExample) 2018-05-17
JP6757312B2 JP6757312B2 (ja) 2020-09-16

Family

ID=54196421

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502932A Expired - Fee Related JP6757312B2 (ja) 2014-03-27 2015-03-26 置換インドールmcl−1阻害剤

Country Status (7)

Country Link
US (3) US10533010B2 (enExample)
EP (1) EP3122353B1 (enExample)
JP (1) JP6757312B2 (enExample)
CN (1) CN106456602B (enExample)
AU (1) AU2015235944B2 (enExample)
CA (1) CA2943815C (enExample)
WO (1) WO2015148854A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10533010B2 (en) 2014-03-27 2020-01-14 Vanderbilt University Substituted indole Mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
JP7086395B2 (ja) * 2016-03-04 2022-06-20 ヴァンダービルト ユニバーシティー 置換インドールMcl-1阻害剤
CR20180499A (es) 2016-04-22 2019-01-25 Astrazeneca Ab Inhibidores de mcl1 macrocicliclos para tratar el cancer
WO2017198341A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
EP3458459B1 (en) * 2016-05-19 2022-04-27 Bayer Aktiengesellschaft Macrocyclic indole derivatives
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
CN111093659A (zh) * 2017-04-30 2020-05-01 财团法人生物技术开发中心 一种抗癌干性的药物
WO2019040511A1 (en) * 2017-08-22 2019-02-28 University Of Maryland Batimore DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS
EP3710451A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Substituted macrocyclic indole derivatives
WO2019096914A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
AR113887A1 (es) 2017-11-17 2020-06-24 Bayer Ag Derivados de indol macrocíclicos sustituidos con cloro
EP3710449B1 (en) 2017-11-17 2022-07-06 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
EP3710456B1 (en) 2017-11-17 2022-09-21 The Broad Institute, Inc. Macrocyclic indole derivatives
WO2019096907A1 (en) 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
CN109988151B (zh) * 2017-12-29 2021-04-23 北京赛特明强医药科技有限公司 一种炔类化合物、制备方法及其应用
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
CN108251104B (zh) * 2018-02-27 2019-11-05 山东大学 一种取代吲哚-2-羧酸类Bcl-2小分子荧光探针及其应用
JP6899975B2 (ja) * 2018-05-14 2021-07-07 ギリアード サイエンシーズ, インコーポレイテッド Mcl−1阻害剤
US11718614B2 (en) 2018-06-25 2023-08-08 Suzhou Mednes Pharma Tech Co., Ltd. Compounds and methods for treatment of hedgehog pathway associated conditions
CN113453724B (zh) 2018-09-27 2025-02-25 皮埃尔法布雷医药公司 基于磺酰基马来酰亚胺的连接子和相应的偶联物
TWI749404B (zh) * 2018-11-22 2021-12-11 大陸商蘇州亞盛藥業有限公司 作為mcl-1抑制劑的大環吲哚
WO2020147802A1 (en) * 2019-01-18 2020-07-23 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic spiroethers as mcl-1 inhibitors
EP3969457B1 (en) 2019-05-17 2025-08-13 The Broad Institute Inc. Methods of preparing macrocyclic indoles
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
WO2024123195A1 (en) * 2022-12-06 2024-06-13 Captor Therapeutics S.A. Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
JP2025540970A (ja) * 2022-12-06 2025-12-17 キャプター セラピューティクス エス.エー. ユビキチンリガーゼ及びターゲットmcl-1タンパク質に結合する二機能性化合物を使用するターゲティングされたタンパク質分解
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections
WO2026148303A1 (en) * 2025-01-06 2026-07-09 Vanderbilt University Macrocyclic mcl-1 inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703053A (en) 1985-10-28 1987-10-27 Warner-Lambert Company Benzothiophenes and benzofurans and antiallergic use thereof
GB8531612D0 (en) 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
US4994477A (en) 1988-03-24 1991-02-19 Abbott Laboratories Heterocyclic renin inhibitors
DE4128015A1 (de) 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US5436264A (en) * 1993-08-19 1995-07-25 Syntex (U.S.A.) Inc. N-aryloxyalkyl tryptamine α1 -adrenergic receptor antagonists
JP3739432B2 (ja) 1994-02-25 2006-01-25 ダイセル化学工業株式会社 オゾン開裂反応
AU2651297A (en) 1996-05-08 1997-11-26 Ihara Chemical Industry Co. Ltd. Indolyl-substituted uracil derivatives and herbicides comprising them as active ingredients
ATE310528T1 (de) 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
FR2761070B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2761073B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
IL154981A0 (en) 2000-10-10 2003-10-31 Smithkline Beecham Corp Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
FR2827287B1 (fr) 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005056522A2 (en) 2003-12-04 2005-06-23 National Health Research Institutes Indole compounds
US7429611B2 (en) 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
US8097644B2 (en) 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
EP2094662B1 (en) 2006-12-14 2012-04-11 Astellas Pharma Inc. Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
MX2009011210A (es) * 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
KR101511074B1 (ko) * 2007-04-16 2015-04-13 애브비 인코포레이티드 7-치환된 인돌 Mcl-1 억제제
US20090270497A1 (en) 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
FR2961393B1 (fr) 2010-06-16 2013-02-15 Oreal Procede de coloration capillaire a partir d'une composition comprenant au moins un compose indolique ou une indolinique, un sel metallique, du peroxyde d'hydrogene et un agent alcalinisant
JP2013537191A (ja) 2010-09-08 2013-09-30 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション p53−Mdm2アンタゴニスト
CN103597073B (zh) 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用
EP2785720B1 (en) 2011-11-29 2017-08-09 Nanjing Allgen Pharma Co. Ltd. Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents
WO2013112878A1 (en) 2012-01-26 2013-08-01 The Penn State Research Foundation Mcl-1 modulating compositions
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
WO2015031608A1 (en) 2013-08-28 2015-03-05 Vanderbilt University Substituted indole mcl-1 inhibitors
US10533010B2 (en) 2014-03-27 2020-01-14 Vanderbilt University Substituted indole Mcl-1 inhibitors
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
JP7086395B2 (ja) 2016-03-04 2022-06-20 ヴァンダービルト ユニバーシティー 置換インドールMcl-1阻害剤

Similar Documents

Publication Publication Date Title
CN110776507B (zh) Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
CN103200822B (zh) 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用
CN110772639B (zh) Bcl-2抑制剂与MDM2抑制剂的组合产品及其在预防和/或治疗疾病中的用途
JP7028809B2 (ja) コルテキソロン17α-バレレートを含む腫瘍治療に用いるための組成物
CN105163584A (zh) 用于治疗癌症的化合物
JP2019516759A5 (enExample)
JP2013529200A5 (enExample)
JP2013526540A5 (enExample)
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2013529199A5 (enExample)
JP2016528246A5 (enExample)
JP2013526538A5 (enExample)
EP3716978B1 (en) N-(phenyl)-n'-(6-quinoxalinyl)-urea derivatives as ikkb inhibitors for the treatment of cancer
JP6889101B2 (ja) グルタミナーゼ阻害剤の結晶形態
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
CN104755455B (zh) 可用于治疗癌症的巨大戟醇衍生化合物
JP2019527239A5 (enExample)
JP2019529475A5 (enExample)
AU2016301212A1 (en) Inhibitors of ACK1/TNK2 tyrosine kinase
CN104470509A (zh) 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途
CN105935357A (zh) 癌细胞凋亡
Banik et al. Novel 6, 12-disubstituted chrysene as potent anticancer agent: synthesis, in vitro and in vivo study
CN107638426B (zh) 噻唑类化合物在制备治疗肿瘤的药物中的用途
JP2020533399A (ja) 新規低分子化合物
TW201231470A (en) 4-anilinofuro[2,3-b]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same